Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 2/2016

01-04-2016 | Original Paper

In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts

Authors: Magda Massae Hata Viveiros, Fabiano Yutaka Kakizaki, Laura Almeida Hércules, Carlos Roberto Padovani, João Manuel Grisi Candeias, Silvana Artioli Schellini

Published in: International Ophthalmology | Issue 2/2016

Login to get access

Abstract

To compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.
Literature
1.
Serracarbassa LL, Dantas MCN (1999) Disordens degenerativas da conjuntiva-córnea-esclera. In: Lima, Dantas MCN; Alves, MR. Doenças externas oculares e córnea—Manual do CBO. Cult Méd São Paulo 8:371–374
2.
Alves MRA (1999) Pterígio In: Conjuntiva Cirúrgica. Roca São Paulo 8:59–66
3.
4.
Cardillo JA, Alves MR, Kara José N, Trajan Neto A, Serpa JF, Ambrósio LE (1995) Uso tópico pós-operatório versus aplicação intra-operatória da mitomicina C a 0,02% na prevenção de recidivas. Arq Bras Oftalmol 58(6):413–415
5.
Cardillo JA, Kara José N, Alves MR, Poterio MB, Coelho RP, Ambrósio LE (1995) Instilação do colírio de mitomicina C no pós-operatório do pterígio primário. Arq Bras Oftalmol 58(2):138–140
6.
Cardillo JA, Alves MR, Kara José N, Camargo JCF, Serpa JF, Ambrósio LE et al (1996) Eficácia da mitomicina C a 0,04% na prevenção de recidivas do pterígio primário: aplicação intra-operatória versus uso tópico pós-operatório. Rev Bras Oftalmol 55(6):15–18
7.
Rubinfeld RS, Stein RM (1997) Topical mitomycin C for pterygia: is single application appropriate? Ophthal Surg Lasers 28(8):662–669
8.
Kheirkhah A, Hashemi H, Adelpour M, Nikdel M, Rajabi MB, Behrouz MJ (2012) Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. Ophthalmology 119(2):227–232CrossRefPubMed
9.
Young AL, Ho M, Jhanji V, Cheng LL (2013) Ten-year results of a randomized controlled trial comparing 0.02 % mitomycin C and limbal conjunctival autograft in pterygium surgery. Ophthalmology 120(12):2390–2395CrossRefPubMed
10.
Malek I, Zghal I, Chebbi A, Lajili Z, Boujemaa C, Nacef L, Bouguila H, Saida Ayed S (2013) Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study. J Fr Ophtalmol 36(3):230–235CrossRefPubMed
11.
Schellini AS, Shiratori CN, Spirandelli PH, Shiratori CA, Padovani CR (2000) Uso do 5-fluorouracil no intra-operatório da cirurgia do pterígio. Arq Bras Oftalmol 63(2):111–114CrossRef
12.
Shiratori CA, Hoyama E, Schellini SA, Padovani CR (2003) Infiltração de 5-fluorouracil no pré-operatório do pterígio. Arq Bras Oftalmol 66(4):499–503CrossRef
13.
Valezi VG, Schellini SA, Viveiros MMH, Padovani CR (2009) Segurança e efetividade no tratamento do Pterígio usando infiltração de 5-fluoruracil no intraoperatório. Arq Bras Oftalmol 72:169–173CrossRefPubMed
14.
Viveiros MMH, Schellini SA, Candeias J, Padovani CR (2007) Exposure of normal Tenon’s capsule fibroblasts from pterygium to 5-fluorouracil and mitomycin C. Arq Bras Oftalmol 70(1):73–77CrossRefPubMed
15.
Bekibele CO, Ashaye A, Olusanya B, Baiyeroju A, Fasina O, Ibrahim AO, Ogun O (2012) 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence. Int Ophthalmol 32(1):3–8CrossRefPubMed
16.
Shahin MM, Elbendary AM, Elwan MM (2012) Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report. Ophthalmic Surg Lasers Imaging 43(6):459–466CrossRefPubMed
17.
Hu Q, Qiao Y, Nie X, Cheng X, Ma Y (2014) Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea 33(2):154–160CrossRefPubMed
18.
Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 31(2):155–161CrossRefPubMed
19.
Gu L, Jin W, Kan L, Wang X et al (2015) A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. Cell Biochem Biophys 71(2):565–570. doi:10.​1007/​s12013-014-0235-7
20.
Umeda K, Adachi S, Tanaka S, Ogawa A, et al (2014) Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. doi:10.​1002/​pbc.​25243
21.
22.
Borel JF (2002) History of the discovery of ciclosporin and of its early    pharmacological developement. Wien Klin Wochenschr 114(12):433–437
23.
24.
Perry HD, Donnenfeld ED (2004) Topical 0,05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5(10):2099–2107CrossRefPubMed
25.
Schultz C (2014) Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 24(6):37–42CrossRef
26.
Zhou XQ, Wei RL (2014) Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea 33(7):760–767CrossRefPubMed
27.
Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al (2002) Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 89(3):289–303CrossRef
28.
Keklikci U, Dursun B, Cingu AK (2014) Topical cyclosporine A 0.05% eyedrops in the treatment of vernal keratoconjunctivitis—randomized placebo-controlled trial. Adv Clin Exp Med 23(3):455–461CrossRefPubMed
29.
Erdinest N, Solomon A (2014) Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol 14(5):457–463CrossRefPubMed
30.
31.
Wan XC, Dimov V (2014) Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol 10(4):543–549CrossRefPubMed
32.
Pflugfelder SC, Karpecki PM, Perez VL (2014) Treatment of blepharitis: recent clinical trials. Ocul Surf 12(4):273–284CrossRefPubMed
33.
Hasanreisoglu M, Avisar R (2008) Long-term topical cyclosporin A therapy in Thygeson’s superficial punctate keratitis: a case report. Cases J 23(1):415CrossRef
34.
Ragam A, Kolomeyer AM, Kim JS, Nayak NV et al (2014) Topical cyclosporine 1 % for the treatment of chronic ocular surface inflammation. Eye Contact Lens 40(5):283–288CrossRefPubMed
35.
Arevalo JF, Lasave AF, Jindan MY, Al Sabaani NA et al (2015) Uveitis in Behçet Disease in a Tertiary Center Over 25 Years: The KKESH Uveitis Survey Study Group. Am J Ophthalmol 159(1):177–184CrossRefPubMed
36.
Wu H, Chen G (1999) Cyclosporine A and thiotepa in prevention of postoperative recurrence of pterygium. Yan Ke Xue Bao 15(2):91–92PubMed
37.
Hasegawa DS, Hoyama E, Dalamas JC, Hasegawa N, Yagui N (2006) Uso de ciclosporina 0.05% colírio no pós-operatório do pterígio (abstract). In: XXX international congress of ophthalmology, São Paulo, 19–24 February 2006. Abstract book. p 64
38.
Turan-Vural E, Torun-Acar B, Kivanc SA, Acar S (2011) The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery. Clin Ophthalmol 5:881–885CrossRefPubMedPubMedCentral
39.
Özülken K, Koç M, Ayar O, Hasiripi H (2012) Topical cyclosporine A administration after pterygium surgery. Eur J Ophthalmol 22(7):5–10CrossRef
40.
Aydin A, Karadayi K, Aykan U, Can G, Colakoglu K, Bilge AH (2008) Effectiveness of topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft. J Fr Ophtalmol 31(7):699–704CrossRefPubMed
41.
Yalcin Tok O, Burcu Nurozler A, Ergun G, Akbas Kocaoglu F, Duman S (2008) Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica 222(6):391–396CrossRefPubMed
42.
Hercules LA, Viveiros MMH, Schellini AS, Candeias J, Padovani CR (2006) Exposure of Tenon’s capsule fibroblasts of pterygium to cyclosporin 0.05%. Arq Bras Oftalmol 69(6):831–835CrossRefPubMed
43.
Viveiros MMH, Schellini AS, Rainho C, Rogatto SR, Padovani CR (2004) Análise do cultivo de fibroblastos da cáspula de Tenon de pterígios primários e recidivados. Arq Bras Oftalmol 67(supl 4):37
44.
45.
Di Girolano N, Kumar RK, Coroneo MT, Wakefield D (2002) UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Inv Ophthalmol Vis Sci 43(11):3430–3437
46.
Nussenblatt RB, Palestine AG (1986) Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 31:159–169CrossRefPubMed
47.
48.
Piccinini F, Tesei A, Paganelli G, Zoli W, Bevilacqua A (2014) Improving reliability of live/dead cell counting through automated image mosaicing. Comput Methods Programs Biomed 117(3):448–463. doi:10.​1016/​j CrossRefPubMed
Metadata
Title
In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts
Authors
Magda Massae Hata Viveiros
Fabiano Yutaka Kakizaki
Laura Almeida Hércules
Carlos Roberto Padovani
João Manuel Grisi Candeias
Silvana Artioli Schellini
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 2/2016
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-015-0106-2

Other articles of this Issue 2/2016

International Ophthalmology 2/2016 Go to the issue

Original Paper

Combined pars plana vitrectomy–scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy

Photo Essay

A case of unilateral hemolacria

Original Paper

Efficacy of Ozurdex implant in recalcitrant diabetic macular edema—a single-center experience

Original Paper

Clinicopathological profile of orbital exenteration: 14 years of experience from a tertiary eye care center in South India

Original Paper

Are our cornea waiting lists dynamic enough?

Original Paper

Cytomorphometric study of epithelial cells in normal and cataractous human lenses in relation with hyperglycemia